NCT06554561View on ClinicalTrials.gov

A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2029

Conditions
PCNSL
Interventions
DRUG

Pomalidomide

3-5mg d1-d14 for 4-6 cycles, every 21 days as induction/consolidation chemotherapy, Then 3-5mg d1-d14 for 12 cycles, every 28 days as maintenance treatment.

DRUG

Rituximab

375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 4-6 cycles will be prescribed.

DRUG

Methotrexate

3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 4-6 cycles will be prescribed.

Trial Locations (1)

310009

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER